Mid-course follow-up
16.3%
Average symptom severity decrease among the 99 users who completed the Phase 3 assessment.
Clinical outcomes
Early Choiceful users report meaningful OCD symptom improvement.
In a rolling internal outcomes analysis, users who completed Choiceful's in-app follow-up assessments showed lower average OCD severity scores as they progressed through the treatment course.
This is an internal, non-IRB-reviewed analysis of self-reported app data from users who completed the assessments. It is not a randomized clinical trial.
Average severity score
12.48 to 8.29
25.1% lower
Onboarding
12.48
Starting average · Baseline
Phase 3
10.34
16.3% decrease · 99 users
Phase 6
8.29
25.1% decrease · 17 users
End-course follow-up
25.1%
Average symptom severity decrease among the 17 users who completed the Phase 6 assessment.
Measure
5 items
A brief Y-BOCS-inspired severity check scored from 0 to 20 and completed inside the app.
How we measure
A brief in-app OCD severity assessment.
Choiceful uses a five-question severity assessment inspired by the Yale-Brown Obsessive Compulsive Scale. Users complete it during onboarding, again around the middle of the treatment course, and again near the end of the course.
Because Choiceful is self-paced, there is no fixed follow-up timeframe. Users complete the course and assessments at their own pace.
The five symptom domains
1
Time occupied by OCD symptoms
2
Interference in daily life
3
Distress caused by OCD symptoms
4
Ability to let intrusive thoughts pass
5
Ability to resist compulsions
Assessment completion
Results reflect users who completed each follow-up.
These numbers are not calculated across all enrolled users. Follow-up completion is voluntary, the course is a paid feature, and users are not enrolled in a formal study or required to complete every assessment.
Phase 3 assessment completed99 users
Phase 6 assessment completed17 users
What this suggests
Among users who progressed far enough to complete follow-up assessments, average self-reported OCD severity moved in the right direction: lower symptoms at the midpoint, and lower still near the end of the course.
Important limitations
- This analysis is self-reported and collected in-app.
- It has not been IRB reviewed.
- It is not randomized and does not include a control group.
- It includes only users who completed follow-up assessments.
We are continuing to measure outcomes as Choiceful grows.
This rolling analysis helps us understand whether users are improving as they move through Choiceful's ERP- and ACT-based treatment course, and where the experience needs to get better.